Ashish M. Kamat

Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

Vitaly Margulis, Shahrokh F. Shariat, Surena F. Matin et al. · Cancer · 2009 · 1.1K citations · Full text

Medicine, Surgery, Urology +13

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Sam S. Chang, Bernard H. Bochner, Roger Chou et al. · The Journal of Urology · 2017 · 940 citations · Full text

Medicine, Oncology, Radiation Oncology +13

CTLA-4 blockade increases IFNγ-producing CD4 ⁺ ICOS ^hi cells to shift the ratio of effector to regulatory T cells in cancer patients

Chrysoula I. Liakou, Ashish M. Kamat, Derek Ng Tang et al. · Proceedings of the National Academy of Sciences · 2008 · 538 citations · Full text

Medicine, Immunology, Oncology +17

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni et al. · The Lancet Oncology · 2021 · 533 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

Bradley Curtis Carthon, Jedd D. Wolchok, Jianda Yuan et al. · Clinical Cancer Research · 2010 · 461 citations · Full text

Life Sciences, Immunology, Oncology +17